Inovio Pharmaceuticals posts flat Q1 net loss

Inovio Pharmaceuticals

13/05/2026 21:23

Overview

US biotech firm reported no Q1 revenue and a net loss of $19.7 mln, flat yr/yr

Operating expenses fell yr/yr due to lower R&D and G&A costs

FDA review of INO-3107 for RRP ongoing; cash runway extends into Q1 2027

Outlook

Company expects cash resources to fund operations into Q1 2027, beyond INO-3107 PDUFA date

Inovio continues commercial readiness plans for potential 2026 launch of INO-3107, pending FDA approval

Company estimates Q2 2026 operational net cash burn of about $18 mln

Result Drivers

LOWER R&D SPENDING - Co attributed decreased R&D expenses to lower employee and consultant compensation, reduced engineering services, and lower expensed inventory

REDUCED G&A COSTS - General and administrative expenses fell due to unspecified reductions compared to prior year

Company press release: ID:nPn2Fl4K7a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.28


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $6.00, about 325.5% above its May 12 closing price of $1.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)